Advertisement

FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma


Advertisement
Get Permission

On January 22, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) as first-line treatment for patients with advanced renal cell carcinoma.

CheckMate 9ER

Efficacy was evaluated in CheckMate 9ER, a randomized, open-label trial in patients with previously untreated advanced renal cell carcinoma. Patients were randomly assigned to receive either nivolumab at 240 mg over 30 minutes every 2 weeks in combination with cabozantinib at 40 mg orally once daily (n = 323) or sunitinib at 50 mg orally daily for the first 4 weeks of a 6-week cycle (4 weeks on treatment, followed by 2 weeks off; n = 328).

The trial demonstrated a statistically significant improvement in progression-free survival, overall survival, and confirmed overall response rate for patients treated with nivolumab plus cabozantinib compared with those who received sunitinib. Median progression-free survival per blinded independent central review was 16.6 months vs 8.3 months (hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.41–0.64). Median overall survival was not reached in either arm (HR = 0.60, 95% CI = 0.40–0.89). Confirmed overall response rate per blinded independent central review was 55.7% and 27.1% in the nivolumab plus cabozantinib and sunitinib arms, respectively.

The most common adverse reactions (≥ 20%) in patients receiving the combination of nivolumab and cabozantinib were diarrhea, fatigue, hepatotoxicity, palmar-plantar erythrodysaesthesia syndrome, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection.

The recommended dose is nivolumab at 240 mg every 2 weeks (30-minute intravenous infusion) or at 480 mg every 4 weeks (30-minute intravenous infusion) in combination with cabozantinib at 40 mg orally once daily without food until disease progression or unacceptable toxicity.

 


Advertisement

Advertisement



Advertisement